• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Disaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Disaccharides

Recent Advances in λ-Carrageenan (9064-57-7) Research: Implications for Biomedical Applications

In recent years, λ-Carrageenan (CAS: 9064-57-7), a sulfated polysaccharide derived from red seaweed, has garnered significant attention in the field of chemical biology and pharmaceutical research. Its unique structural properties, including high sulfate content and flexible helical conformation, make it a promising candidate for various biomedical applications, ranging from drug delivery systems to antiviral therapies. This research brief synthesizes the latest findings on λ-Carrageenan, highlighting its mechanisms of action, therapeutic potential, and recent innovations in its application.

A 2023 study published in Carbohydrate Polymers elucidated the molecular interactions between λ-Carrageenan and viral envelope proteins, demonstrating its potent inhibitory effects against enveloped viruses such as SARS-CoV-2 and HSV-1. The research team employed surface plasmon resonance (SPR) and molecular docking simulations to reveal that the sulfate groups of λ-Carrageenan competitively bind to viral glycoproteins, thereby blocking host cell entry. These findings underscore its potential as a broad-spectrum antiviral agent, particularly in topical formulations for mucosal protection.

Parallel advancements in drug delivery systems have leveraged λ-Carrageenan's mucoadhesive properties. A breakthrough study in Journal of Controlled Release (2024) developed pH-responsive nanoparticles using λ-Carrageenan as a coating material. The nanoparticles exhibited sustained release of doxorubicin in tumor microenvironments (pH 6.5) while remaining stable in systemic circulation (pH 7.4). This dual functionality addresses a critical challenge in oncology therapeutics—reducing off-target toxicity while enhancing tumor accumulation.

From a structural perspective, recent NMR analyses (2024) have resolved long-standing questions about λ-Carrageenan's conformation dynamics. Contrary to previous assumptions, the 3,6-anhydrogalactose residues in λ-Carrageenan (9064-57-7) display unexpected flexibility in physiological conditions, enabling adaptive binding to diverse molecular targets. This plasticity may explain its efficacy as both a gel-forming agent in tissue engineering scaffolds and as a molecular scaffold for enzyme immobilization in biocatalysis.

Industrial applications are also evolving, with GMP-grade λ-Carrageenan now being produced under stringent regulatory guidelines (USP-NF 2024 monograph updates). The elimination of pyrogenic contaminants during extraction processes has expanded its utility in parenteral formulations, as evidenced by Phase I clinical trials of λ-Carrageenan-based heparin alternatives for anticoagulation therapy.

Looking forward, researchers are exploring hybrid systems combining λ-Carrageenan with metallic nanoparticles (e.g., silver or gold) for antimicrobial wound dressings. Preliminary results presented at the 2024 Materials in Medicine Symposium showed a 4-log reduction in MRSA biofilm formation when using λ-Carrageenan-silver nanocomposites, attributed to synergistic effects between the polysaccharide's immunomodulatory properties and silver's bactericidal activity.

In conclusion, the multifaceted applications of λ-Carrageenan (9064-57-7) continue to expand across the biomedical spectrum. Ongoing research is expected to further refine its structure-activity relationships, particularly in the context of personalized medicine where its modifiable sulfate patterning could enable patient-specific therapeutic designs. The compound's natural origin, biocompatibility, and regulatory acceptance position it as a sustainable material for next-generation medical solutions.

• 11114-20-8(κ-Carrageenan)
• 210357-34-9(a-D-Glucopyranoside, methyl,tetrakis(hydrogen sulfate), potassium salt (9CI))
• 37209-31-7(Detralfate (9CI))
• 37191-69-8(β-Cyclodextrin Hydrogen Sulfate Sodium Salt)
• 121369-51-5(beta-Cyclodextrin, tetradecakis(hydrogen sulfate))
• 37300-21-3(Pentosan Polysulfate)
• 131511-43-8(a-L-Galactopyranoside, methyl6-deoxy-2-O-(6-deoxy-a-L-galactopyranosyl)-, 3-(hydrogen sulfate), monosodium salt (9CI))
• 131511-45-0(a-L-Galactopyranoside, methyl6-deoxy-2-O-(6-deoxy-a-L-galactopyranosyl)-, 4-(hydrogen sulfate), monosodium salt (9CI))
• 9062-07-1(ι-Carrageenin)
• 159358-51-7(Lactose-3’-sulfate)